Navigation Links
General Nutrition Centers, Inc. Reports First Quarter 2008 Financial Results

PITTSBURGH, May 8 /PRNewswire/ -- General Nutrition Centers, Inc. ("GNC" or the "Company"), the largest global specialty retailer of nutritional supplements, today reported its financial results for the first quarter ended March 31, 2008.

The Company is an indirect wholly owned subsidiary of GNC Parent LLC which was acquired on March 16, 2007 by affiliates of Ares Management LLC ("Ares") and Ontario Teachers' Pension Plan Board ("Teachers"). As such, the financial results presented in this press release represent the aggregate of the financial results of General Nutrition Centers, Inc. from January 1, 2007 through March 15, 2007, predecessor, and the results from March 16, 2007 to March 31, 2007 and for the three months ended March 31, 2008, successor.

For the first quarter of 2008, the Company reported revenues of $428.1 million, a 9.2% increase over the same quarter in 2007. This increase was the result of increased revenues in each of the Company's business segments: Retail by 5.5%; Franchise by 10.4%; and Manufacturing/Wholesale by 47.5%. Same store sales improved 2.2% in domestic company-owned stores (including internet sales), and 2.6% in Canadian stores. Domestic same store sales were negatively impacted by approximately 0.6% due to the shift of the Easter holiday to the first quarter in 2008, compared to the second quarter in the prior year.

For the first quarter 2008, the Company reported earnings before interest, income taxes, depreciation and amortization (EBITDA) of $54.9 million compared to $(4.1) million for the same quarter in 2007. Included in the first quarter of 2007 was $51.3 million of transaction costs and related expenses resulting from the acquisition of the Company by Ares and Teachers. Also, included as part of compensation expense for the first quarters of 2008 and 2007 was $0.7 million and $0.5 million, respectively, of non-cash stock-based compensation expense. Excluding the non-cash stock compensation expense and the acquisition related charges, Adjusted EBITDA was $55.6 million for the first quarter of 2008, a 16.6% increase over Adjusted EBITDA of $47.7 million for the first quarter of 2007, a result of improved operating income in each of our business segments.

The transaction costs and acquisition-related expenses incurred in the first quarter of 2007 included: $34.6 million of transaction fees and expenses; $15.3 million of compensation expenses (including $3.8 million of non-cash stock-based compensation resulting from the cancellation of all outstanding stock options); and $1.4 million of non-cash purchase accounting adjustments recorded as part of cost of sales.

GNC, headquartered in Pittsburgh, Pa., is the largest global specialty retailer of nutritional products including vitamin, mineral, herbal and other specialty supplements and sports nutrition, diet and energy products. GNC has more than 5,000 retail locations throughout the United States (including more than 950 franchise and 1,400 Rite Aid store-within-a-store locations) and franchise operations in 43 international markets. The company -- which is dedicated to helping consumers Live Well -- also offers products and product information online at

GNC has scheduled a conference call and webcast to report its first quarter financial results on Thursday, May 8, 2008 at 11:00 am ET. To listen to this call inside the U.S., dial 1-800-588-4973, and outside the U.S. dial 1-847-413-2407. A webcast of the call will be available through the "About GNC" link on The conference identification number for all callers is 21531200.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to our financial condition, results of operations and business that is not historical information. Forward-looking statements can be identified by the use of terminology such as "subject to," "believes," "anticipates," "plans," "expects," "intends," "estimates," "projects," "may," "will," "should," "can," the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. GNC believes there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain, we may not realize our expectations and our beliefs may not prove correct. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. Actual results could differ materially from those described or implied by such forward-looking statements. Factors that may materially affect such forward- looking statements include, among others:

-- significant competition in our industry;

-- unfavorable publicity or consumer perception of our products;

-- the incurrence of material products liability and product recall costs;

-- costs of compliance and our failure to comply with governmental


-- the failure of our franchisees to conduct their operations profitably

and limitations on our ability to terminate or replace under-performing


-- economic, political and other risks associated with our international


-- our failure to keep pace with the demands of our customers for new

products and services;

-- the lack of long-term experience with human consumption of some of our

products with innovative ingredients;

-- disruptions in our manufacturing system or losses of manufacturing


-- increases in the frequency and severity of insurance claims,

particularly for claims for which we are self-insured;

-- loss or retirement of key members of management;

-- increases in the cost of borrowings and unavailability of additional

debt or equity capital;

-- the impact of our substantial indebtedness on our operating income and

our ability to grow;

-- the failure to adequately protect or enforce our intellectual property

rights against competitors;

-- changes in applicable laws relating to our franchise operations; and

-- our inability to expand our franchise operations to attract new


Results of Operations

(Dollars in millions and percentages expressed as a percentage of total

net revenues)

Successor Combined

Three Months Three Months

Ended March 31, Ended March 31,

2008 2007


Retail $321.3 75.0% $304.7 77.8%

Franchise 64.9 15.2% 58.8 15.0%

Manufacturing / Wholesale 41.9 9.8% 28.4 7.2%

Total net revenues 428.1 100.0% 391.9 100.0%

Operating expenses:

Cost of sales, including

warehousing, distribution

and occupancy costs 278.9 65.1% 255.0 65.1%

Compensation and related

benefits 61.6 14.5% 74.4 19.0%

Advertising and promotion 18.1 4.2% 20.7 5.3%

Other selling, general and

administrative expenses 21.8 5.1% 19.5 4.9%

Amortization expense 3.1 0.7% 1.2 0.3%

Foreign currency loss (gain) 0.1 0.0% (0.1) 0.0%

Transaction related costs - 0.0% 34.6 8.8%

Total operating expenses 383.6 89.6% 405.3 103.4%

Operating income:

Retail 36.8 8.6% 33.5 8.6%

Franchise 19.8 4.6% 17.4 4.4%

Manufacturing / Wholesale 15.8 3.7% 12.3 3.1%

Unallocated corporate and other


Warehousing and distribution

costs (13.8) -3.2% (12.7) -3.2%

Corporate costs (14.1) -3.3% (29.3) -7.5%

Merger related costs - 0.0% (34.6) -8.8%

Subtotal unallocated corporate

and other costs, net (27.9) -6.5% (76.6) -19.5%

Total operating income (loss) 44.5 10.4% (13.4) -3.4%

Interest expense, net 23.1 47.3

Income (loss) before income taxes 21.4 (60.7)

Income tax expense (benefit) 8.1 (10.2)

Net income (loss) $13.3 $(50.5)

Note: The numbers in the above table have been rounded to millions. All

calculations related to the Results of Operations for the

year-over-year comparisons were derived from the table above and

could occasionally differ immaterially if you were to use the

unrounded data for these calculations.

We define EBITDA as net income (loss) before interest expense (net), income tax expense, depreciation, and amortization. Management uses EBITDA as a tool to measure operating performance of the business. We use EBITDA as one criterion for evaluating our performance relative to our competitors and also as a measurement for the calculation of management incentive compensation. Although we primarily view EBITDA as an operating performance measure, we also consider it to be a useful analytical tool for measuring our liquidity, our leverage capacity, and our ability to service our debt and generate cash for other purposes.

We also use EBITDA as defined in our Senior Credit Facility, and the indentures governing our Senior Floating Rate Toggle Notes and Senior Subordinated Notes to determine compliance with the terms of these facilities and Notes. The reconciliation of EBITDA as presented below is different than that used for purposes of the covenants under the indentures governing the Senior Floating Rate Toggle Notes and Senior Subordinated Notes. The reconciliation of EBITDA as presented below is different than that used in our Senior Credit Facility and the indentures governing the Senior Floating Rate Toggle Notes and Senior Subordinated Notes. Historically, we have highlighted our use of EBITDA as a liquidity measure and for related purposes because of our focus on the holders of our debt. At the same time, however, management has also internally used EBITDA as a performance measure. EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net income, operating income, or any other performance measures derived in accordance with GAAP, or as an alternative to GAAP cash flow from operating activities, as a measure of our profitability or liquidity.

Adjusted EBITDA is presented as additional information, as management also uses Adjusted EBITDA to evaluate the operating performance of the business and as a measurement for the calculation of management incentive calculation. Management believes that EBITDA and Adjusted EBITDA are commonly used by security analysts, lenders, and others; however, EBITDA and Adjusted EBITDA may not be comparable to other similarly titled measures reported by other companies, limiting their usefulness as comparative measures.
Some of the limitations of EBITDA and Adjusted EBITDA are as follows:

-- EBITDA and Adjusted EBITDA do not reflect cash expenditures, future

requirements for capital expenditures, or contractual commitments;

-- EBITDA and Adjusted EBITDA do not reflect changes in, or cash

requirements for working capital needs;

-- EBITDA and Adjusted EBITDA does not reflect interest expense or the

cash requirement necessary to service interest or principal payments on

our debt; although depreciation and amortization are non-cash charges,

the assets being depreciated and amortized will often have to be

replaced in the future, and EBITDA and Adjusted EBITDA do not reflect

any cash requirements for such replacements; and

-- EBITDA and Adjusted EBITDA reflect the impact of earnings on income

resulting from matters we consider not to be indicative of our ongoing

operations, certain of which income we eliminated in our computation of

EBITDA and Adjusted EBITDA.

Because of these limitations, EBITDA and Adjusted EBITDA should not be considered as measures of discretionary cash available to us to invest in our business. We compensate for these limitations by relying primarily on our GAAP results and using EBITDA only for supplemental purposes.

For the combined predecessor and successor periods ended March 31, 2007 and the three months ended March 31, 2008 the following table presents EBITDA reconciled to our net income for such periods and Adjusted EBITDA reconciled to EBITDA for such periods.


(in millions)

(unaudited) Successor Combined

Three Months Ended

March 31,

2008 2007

Net income (loss) $13.3 $(50.5)

Interest expense, net 23.1 47.3

Income tax expense (benefit) 8.1 (10.2)

Depreciation and amortization 10.4 9.3

EBITDA $54.9 $(4.1)

Transaction costs - 34.6

Compensation expense related to transaction - 15.3

Non-cash stock based compensation expense 0.7 0.5

Purchase accounting adjustments - 1.4

Adjusted EBITDA $55.6 $47.7

For the combined predecessor and successor periods ended March 31, 2007 and the three months ended March 31, 2008 the following table presents EBITDA reconciled to our cash from operations for such periods and Adjusted EBITDA reconciled to EBITDA for such periods.


(in millions)

(unaudited) Successor Combined

Three Months Ended

March 31,

2008 2007

Net cash provided by (used in)

operating activities $7.1 $(44.6)

Cash paid for interest (excluding

deferred financing fees) 33.4 38.8

Cash paid for taxes 1.4 1.3

Increase (decrease) in accounts receivable (0.5) 1.9

Increase (decrease) in inventory 21.5 (4.6)

Decrease (increase) in accounts payable (25.5) (4.4)

Increase (decrease) in other assets (0.6) 0.4

Decrease (increase) in other liabilities 18.1 7.1

EBITDA $54.9 $(4.1)

Transaction costs - 34.6

Compensation expense related to transaction - 15.3

Non-cash stock based compensation expense 0.7 0.5

Purchase accounting adjustments - 1.4

Adjusted EBITDA $55.6 $47.7

SOURCE General Nutrition Centers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cephalon Appoints Gerald J. Pappert as General Counsel
2. ACP hosts largest medical education meeting for general and subspecialty internists
3. Wage Complaint Forwarded to Attorney General for Prosecution
4. U.S. Surgeon General Launches New Effort to Address Childhood Obesity
5. Number of U.S. General Surgeons in Decline
6. Academy of General Dentistry Releases Updated Employment Statistical Map
7. Auditor General Jack Wagner to Tour Gino J. Merli Veterans Center in Scranton
8. Pennsylvania Attorney General Corbett, American Lung Association & Others Call for New MSA Funds to Be Used for Tobacco Prevention and Cessation
9. Haemacure Reports on its annual general and special meeting of shareholders
10. AVMA Opens Online Resource to General Public
11. SAIC Awarded $16 Million Contract by General Services Administration
Post Your Comments:
(Date:10/10/2015)... (PRWEB) , ... October 10, 2015 , ... The Bank ... Speedway in Concord, NC. Saturday, October 10th, defending race winner, Kevin Harvick, ... Logano, Matt Kenseth, Dale Earnhardt Jr., and all of the stars of the NASCAR ...
(Date:10/10/2015)... ... October 10, 2015 , ... Well-known Eastern ... to be recognized by The National Law Journal for inclusion in their second ... firms across the United States who obtained the largest awards for their personal ...
(Date:10/9/2015)... , ... October 09, 2015 , ... ... highly sought after internships at the pre-eminent organization in global health: the World ... eliminating social and health disparities. These internships are a mechanism for WHO to ...
(Date:10/9/2015)... PITTSBURGH, PA (PRWEB) , ... October 09, 2015 , ... ... problem of our canes falling when leaned against something," said an inventor from Buffalo, ... that most cane users face daily." , The CANE REST enables a user to ...
(Date:10/9/2015)... , ... October 09, 2015 , ... Head Over Heels ... the elite developmental camp at the Karolyi Ranch in Huntsville, Texas on October 17-21. ... Head Over Heels girls team head coach and executive director, said. “It's a stepping ...
Breaking Medicine News(10 mins):
... have found the first evidence that a specific form of ... the risk for estrogen-induced cancers of the breast and uterus. ... animal equivalent of multiple sclerosis. , IMPACT: ... anti-inflammatory drugs to help prevent flare-ups of their physical symptoms, ...
... even a few days can negatively impact recovery, study ... stroke patients who stop taking their cholesterol-lowering statin drugs ... their long-term risk of death and disability, researchers report. ... -- which include drugs like Crestor, Pravachol and Zocor ...
... some people may spend part of the Labor Day weekend ... are satisfied with their jobs, a new University of Chicago ... increases with age, with workers over 65 among the most ... people interviewed between 1972 and 2006 said they were satisfied ...
... 27, 2007) University of Minnesota researchers have ... abnormalities, but show no symptoms of cardiovascular disease, ... the heart and blood vessels., In a recent ... early markers for cardiovascular disease, based on a ...
... New findings that one in 20 North Carolina ... crystal methamphetamine during the previous month suggests increased risk ... according to researchers from Wake Forest University School of ... use among 1,189 MSM was 30 times higher than ...
... Though the overall incidence of head and neck cancers ... oropharyngeal (chiefly, tonsil and base of tongue) cancers is ... and these trends are likely due to oncogenic human ... 1, 2007 issue of CANCER, a peer-reviewed journal of ...
Cached Medicine News:
(Date:10/9/2015)... Calif. , Oct. 9, 2015 AcelRx Pharmaceuticals, ... will be made at the annual European Society of Emergency ... to October 14 th , 2015 at the Lingotto Congress ... EuSEM is the largest meeting of emergency medicine practitioners in ... countries represented. Data from the previously announced phase ...
(Date:10/9/2015)... 2015 Ansun BioPharma announced a presentation at ... ) regarding the compassionate use of DAS181 under an ... who was co-infected with influenza and parainfluenza (Abstract # ... O 2 requirement was reduced and the patient,s ... go off the respirator on day 5. Between day ...
(Date:10/9/2015)... -- Der " JCA-Mauvernay Award   2015 ... und Dr.   Junko Takita    --> Der ... geht an Dr.   Yutaka Kondo und Dr.   ... JCA-Mauvernay Award   2015 " geht an Dr. ...    ™ , das weltweit tätige Schweizer Biopharmazieunternehmen, wird am ...
Breaking Medicine Technology:
... The Detroit Medical Center (DMC) Cardiovascular Institute (CVI) ... to successfully open a patient,s blocked artery with a ... drill" to painlessly remove the plaque buildup which causes ... – conducted Wednesday by CVI Director of Endovascular Medicine ...
... HistoRx, the leader in quantitative immunohistochemistry, advances ... recent issuance of US patents covering key features ... results.  The U.S. Patent and Trademark Office has ... for standardization of digital microscopy instruments, methods required ...
Cached Medicine Technology:
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
... CODMAN EDS 3 CSF External Drainage System was ... and physicians. The clinicians who work every day ... CODMAN EDS 3: ease-of-use in an integrated pole ... valve, accurate hydrostatic leveling from a unique laser ...
Monitorr ICP external CSF drainage and monitoring system with patient line one way valve....
... Specifically designed for neuro and skull ... craniotomies, cranioplasties, craniofacial surgery, pediatric neurosurgery, ... orbital, and skull base regions, neuro ... instruments and implants in one compact ...
Medicine Products: